US Pharma MarketingRelay ‘full steam ahead’ on PI3K inhibitor fueled by first phase 2 data in blood vessel disorder
Relay ‘full steam ahead’ on PI3K inhibitor fueled by first phase 2 data in blood vessel disorder is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Relay Therapeutics’ R&D chief remains convinced the biotech’s PI3Kα inhibitor will carve out its own niche after reporting a slice of phase 2 data in patients with a type of blood vessel disorder.
Source: FierceBiotech